CAR-T Meeting 2023 | CAR-T cell therapy: current applications and how to improve treatment strategies in the future
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, comments on the growing role of CAR-T cell therapy in hematological malignancies, and further highlights the importance of selecting the best strategies and combination approaches to treat patients. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
In all of these different diseases for which CAR- T cell activity has been proven, we pretty much face the same dilemma: how can we provide access earlier in the course of the disease? And also, how can CAR-T cells compare with other innovative approaches, including bispecific, trispecific, whatever specific antibodies that are coming to the market. I like to stress the fact that maybe CAR-T cells are no longer an innovation...
In all of these different diseases for which CAR- T cell activity has been proven, we pretty much face the same dilemma: how can we provide access earlier in the course of the disease? And also, how can CAR-T cells compare with other innovative approaches, including bispecific, trispecific, whatever specific antibodies that are coming to the market. I like to stress the fact that maybe CAR-T cells are no longer an innovation. There are more recent drugs that we have brought to the market and it becomes really complex to decide on the best sequence, best combination of these different approaches based on the available data. We know that we don’t have the resource to carry on all the needed randomized clinical trials, and we need to be inventive in the future to design the best available strategies for patients.
Read more...
Disclosures
BELLICUM PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
BMS/CELGENE: Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
EBMT: Membership on an entity’s Board of Directors or advisory committees
FRESENIUS KABI: Research Funding
KITE/GILEAD: Honoraria, Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
JANSSEN PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
JAZZ: Honoraria
MILTENYI BIOTECH: Research Funding
NOVARTIS: Speakers Bureau
SANOFI SA: Speakers Bureau, Honoraria, Research Funding
TERUMO BCT: Speakers Bureau
